Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the <i>σ</i><sub>1</sub> chaperone protein.

导出 LinkOut

翻译打印收藏纠错

第一作者： Laura,García-Pupo

第一单位： Department of Neurochemistry, Cuban Center for Neurosciences, Cubanacan, Playa, Havana CP 11600, Cuba.

作者： Laura,García-Pupo ^[1] ; Lucie,Crouzier ^[2] ; Alberto,Bencomo-Martínez ^[1] ; Johann,Meunier ^[2] ; Axelle,Morilleau ^[2] ; Benjamin,Delprat ^[2] ; Marquiza Sablón,Carrazana ^[1] ; Roberto,Menéndez Soto Del Valle ^[1] ; Tangui,Maurice ^[2] ; Chryslaine,Rodríguez-Tanty ^[1]

作者单位： Department of Neurochemistry, Cuban Center for Neurosciences, Cubanacan, Playa, Havana CP 11600, Cuba. ^[1] MMDN, University of Montpellier, EPHE, INSERM, Montpellier 34095, France. ^[2]

关键词 Alzheimer's disease Amyloid-β aggregation Drug discovery Learning and memory Molecular modelisation Neuroprotection Zebrafish model σ1 receptor

DOI 10.1016/j.apsb.2024.06.013

PMID 39525570

发布时间 2024-11-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Acta pharmaceutica Sinica. B

2024年14卷10期

4345-4359页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the <i>σ</i><sub>1</sub> chaperone protein.

Acta pharmaceutica Sinica. B

相似文献

Acta pharmaceutica Sinica. B

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the <i>σ</i><sub>1</sub> chaperone protein.

Acta pharmaceutica Sinica. B

相似文献

Acta pharmaceutica Sinica. B

相关期刊

检索历史清除